LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

3.63 -4.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.6

Max

3.8

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6M -12M
Verkoop	554K 18M
Winstmarge	-65.968
Werknemers	226
EBITDA	1.6M -9.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+65.71% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-2.5M 121M
Vorige openingsprijs	8.1
Vorige sluitingsprijs	3.63

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 mrt 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mrt 2026, 22:36 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Government Rules Out Boots on the Ground in the Middle East

30 mrt 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mrt 2026, 21:00 UTC

Winsten

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mrt 2026, 20:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mrt 2026, 23:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 23:40 UTC

Marktinformatie

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mrt 2026, 23:36 UTC

Marktinformatie

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mrt 2026, 23:12 UTC

Marktinformatie

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mrt 2026, 22:49 UTC

Marktinformatie

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mrt 2026, 22:44 UTC

Marktinformatie

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mrt 2026, 22:43 UTC

Marktinformatie

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mrt 2026, 22:42 UTC

Marktinformatie

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mrt 2026, 22:18 UTC

Marktinformatie

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mrt 2026, 22:05 UTC

Marktinformatie

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mrt 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mrt 2026, 21:36 UTC

Acquisities, Fusies, Overnames

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mrt 2026, 21:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 21:25 UTC

Marktinformatie

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mrt 2026, 21:03 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 mrt 2026, 20:09 UTC

Winsten

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mrt 2026, 20:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

65.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 65.71%

Hoogste 10 USD

Laagste 3.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.